Interleukin (IL)-10-producing B cells (B10 cells) have emerged as important regulatory elements with immunosuppressive roles. Chronic lymphocytic leukemia (CLL) B cells also secrete IL-10 and share ...
As per DelveInsight's analysis, the total market size of BAFF- and APRIL-targeted therapies in the 7MM is expected to surge significantly by 2034. BAFF and APRIL-targeted therapies are actively being ...
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the ”Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on ...
Studies examining the binding of B cell activating factor (BAFF) and APRIL (a proliferation-inducing ligand) to their receptors have revealed additional layers of complexity. Trimeric forms of both ...
LOS ANGELES & LONDON & BEIJING--(BUSINESS WIRE)--AKSO Biopharmaceutical, Inc. (“AKSO”), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune ...
Genomewide association studies of autoimmune diseases have mapped hundreds of susceptibility regions in the genome. However, only for a few association signals has the causal gene been identified, and ...
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback